Companies › Tarsus Pharmaceuticals
2 active drug programs in 2 registered trials: 2 Phase 2; Infectious disease, Ophthalmology; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TP-05 (lotilaner) Isoxazoline ectoparasiticide; potassium channel blocker | – | Phase 2 | Lyme Disease | Oct 2027 |
| TP-06 | – | Phase 2 | Persistent Corneal Epithelial Defect | Jul 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07562087 | TP-05 (lotilaner) | Phase 2 | Lyme Disease | Infectious disease | Oct 2027 |
| NCT07886268 | TP-06 | Phase 2 | Persistent Corneal Epithelial Defect | Ophthalmology | Jul 2028 |
Cash and short-term investments of $310m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Bausch & Lomb Alimera Sciences Vantage Biosciences Hyundai Bioscience Sunhawk Vision Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.